Maxidex® 0.1% (dexamethasone ophthalmic suspension) Sterile

Manufacturer
ALCON LABORATORIES, INC.
Effective date
2006-08-21
Label type
Human Prescription Drug Label
Version
1
Source
full-release
Hydrated at
2026-05-31 20:07:10

Label at a glance#

ProductMaxidex
Label structure9 sections

Indications and uses

Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from...

Dosage and administration

SHAKE WELL BEFORE USING. One or two drops topically in the conjunctival sac(s). In severe disease, drops may be used hourly, being tapered to discontinuation as the inflammation subsides. In mild disease, drops may be used up to four to six times daily.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION section

MAXIDEX® 0.1% (dexamethasone ophthalmic suspension) is an adrenocortical steroid prepared as a sterile topical ophthalmic suspension. The active ingredient is represented by the chemical structure:

DESCRIPTIONDESCRIPTION

Each mL contains

Active: dexamethasone 0.1%. Preservative: benzalkonium chloride 0.01%. Vehicle: hypromellose 0.5%. Inactives: sodium chloride, dibasic sodium phosphate, polysorbate 80, edetate disodium, citric acid and/or sodium hydroxide (to adjust pH), purified water.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY section

Dexamethasone suppresses the inflammatory response to a variety of agents and it probably delays or slows healing.

INDICATIONS AND USAGE

INDICATIONS AND USAGE section

Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

CONTRAINDICATIONS

CONTRAINDICATIONS section

Contraindicated in epithelial herpes simplex (dendritic keratitis), vaccinia, varicella, and most other viral diseases of the cornea and conjunctiva; tuberculosis of the eye; fungal disease of ocular structures; and in those persons who have shown hypersensitivity to any component of this preparation.

WARNINGS

WARNINGS section

Prolonged use may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical corticosteroids. In acute purulent conditions of the eye, corticosteroids may mask infection or enhance existing infection. If these products are used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients.

Employment of corticosteroid medication in the treatment of herpes simplex other than epithelial herpes simplex keratitis, in which it is contraindicated, requires great caution; periodic slit-lamp microscopy is essential.

PRECAUTIONS

PRECAUTIONS section

General

General section

FOR TOPICAL OPHTHALMIC USE ONLY. The possibility of persistent fungal infections of the cornea should be considered after prolonged corticosteroid dosing.

Information for Patients

Information for Patients section

Do not touch dropper tip to any surface, as this may contaminate the contents. The preservative in MAXIDEX® (dexamethasone ophthalmic suspension), benzalkonium chloride, may be absorbed by soft contact lenses. MAXIDEX® (dexamethasone ophthalmic suspension) should not be administered while wearing soft contact lenses.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis, Mutagenesis, Impairment of Fertility section

Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of MAXIDEX® dexamethasone ophthalmic suspension).

Pregnancy

Pregnancy section

Pregnancy Category C

Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application in multiples of the therapeutic dose.

In the mouse, corticosteroids produce fetal resorptions and a specific abnormality, cleft palate. In the rabbit, corticosteroids have produced fetal resorptions and multiple abnormalities involving the head, ears, limbs, palate, etc.

There are no adequate or well-controlled studies in pregnant women. MAXIDEX® (dexamethasone ophthalmic suspension) should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be observed carefully for signs of hypoadrenalism.

Nursing Mothers

Nursing Mothers section

Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when MAXIDEX® (dexamethasone ophthalmic suspension) is administered to a nursing woman.

Pediatric Use

Pediatric Use section

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

Geriatric Use section

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS

ADVERSE REACTIONS section

Glaucoma with optic nerve damage, visual acuity and field defects; cataract formation; secondary ocular infection following suppression of host response; and perforation of the globe may occur.

DOSAGE AND ADMINISTRATION

DOSAGE AND ADMINISTRATION section

SHAKE WELL BEFORE USING. One or two drops topically in the conjunctival sac(s). In severe disease, drops may be used hourly, being tapered to discontinuation as the inflammation subsides. In mild disease, drops may be used up to four to six times daily.

HOW SUPPLIED

HOW SUPPLIED section

MAXIDEX® (dexamethasone ophthalmic suspension) in plastic DROP-TAINER® dispensers:

5 mL NDC 0998-0615-05

15 mL NDC 0998-0615-15

STORAGE

Store upright at 8°-27°C (46°-80°F).

Rx Only

© 2003 Alcon, Inc.

HOW SUPPLIEDHOW SUPPLIED

ALCON LABORATORIES, INC.
Fort Worth, Texas 76134 USA
Printed in USA

340907-0803

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
309692dexAMETHasone 0.1 % Ophthalmic SuspensionPSN1
205669Maxidex 0.1 % Ophthalmic SuspensionPSN1
205669dexamethasone 1 MG/ML Ophthalmic Suspension [Maxidex]SBD1
309692dexamethasone 1 MG/ML Ophthalmic SuspensionSCD1
309692dexamethasone 0.1 % Ophthalmic SuspensionSY1
205669Maxidex 0.1 % Ophthalmic SuspensionSY1
205669Maxidex 1 MG/ML Ophthalmic SuspensionSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
DEXAMETHASONE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
1ea46721-9071-6b81-fd0a-a82bfbb014ecProduct name720250220
525701df-f985-480d-995a-e0ee70c2bdf4Product name520250128
ea50b939-d92a-4100-84f5-1c1089663837Product name220240705
941f67d9-7f03-56d2-750c-36de24f654dbProduct name320221117
d7d46a10-8766-d3c8-ebf2-2ccd9efdcae8Product name220220506
7b2c58e8-5850-4e3e-82e9-b1593b1de761Product name520220210
81e34474-b0a5-434f-8104-25d689efc99eProduct name120200303
05ab9c01-cd9a-4f59-b2e8-ddcb887cac39Product name120190408
0c7dba41-c919-5809-508d-4affe6cfcff2Product name220170817
399647c0-db89-02d1-991c-0c17b584482cProduct name120140508
3e9a6377-704f-dff7-b19f-56c98d40c444Product name120140508
4d2e6ff9-14f5-b84f-c39b-373b005712c1Product name120140508
725d71bf-f956-5cad-e556-fa39cb060dc8Product name120140508
9ea85abb-fa68-5da6-ab60-2c7eef579000Product name120140508
d029211e-5e6b-725f-3696-ac6ff77da222Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0998-0615-04Maxidex5 mL in 1 BOTTLE, PLASTICSUSPENSION/ DROPS51
0998-0615-05Maxidex5 mL in 1 BOTTLE, PLASTICSUSPENSION/ DROPS51
0998-0615-06Maxidex5 mL in 1 BOTTLE, PLASTICSUSPENSION/ DROPS51
0998-0615-15Maxidex15 mL in 1 BOTTLE, PLASTICSUSPENSION/ DROPS151

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0998-0615MAXIDEX (DEXAMETHASONE) SUSPENSION/ DROPS [ALCON LABORATORIES, INC.]1Legacy NDC, 4 package rows20080313_a0aa9dc9-265c-4dd6-9b03-276a47217839.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0998-0615-05ML - Milliliter0998-061525e1e147-7af3-4842-b34a-a7310b825a2312012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
dexamethasoneACTIVE INGREDIENT7S5I7G3JQL1
dexamethasoneACTIVE MOIETY7S5I7G3JQL1
benzalkonium chlorideINACTIVE INGREDIENT1
citric acid and/or sodium hydroxideINACTIVE INGREDIENT1
dibasic sodium phosphateINACTIVE INGREDIENTGR686LBA741
edetate disodiumINACTIVE INGREDIENT7FLD91C86K1
hypromelloseINACTIVE INGREDIENT1
polysorbate 80INACTIVE INGREDIENT1
sodium chlorideINACTIVE INGREDIENT451W47IQ8X1
waterINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 10 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0998-06150998-0615-04, 0998-0615-05, 0998-0615-15, 0998-0615-06

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 6 · 354 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION / INTRAMUSCULAR90 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOAP / TOPICAL1.26 %w/wExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / INTRATHECAL9 mgExact identifier — unii candidate
134 equally ranked IID candidates
hypromelloseHYPROMELLOSE3NXW29V3WOLOTION / TOPICAL7 mgName fallback — name candidate
27 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HCONCENTRATE / ORAL1 mg/1mlName fallback — name candidate
78 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HINJECTION / INTRASYNOVIAL0.2 %w/vName fallback — name candidate
78 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XGRANULE, FOR SUSPENSION / ORAL162 mgExact identifier — unii candidate
134 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HPASTE / ORAL28 mgName fallback — name candidate
78 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KSOLUTION / INTRAVENOUS0.05 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KCREAM / TOPICAL14 mgExact identifier — unii candidate
77 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HCREAM / VAGINAL0.4 %w/wName fallback — name candidate
78 equally ranked IID candidates
hypromelloseHYPROMELLOSE3NXW29V3WOSYSTEM / TOPICAL54 mgName fallback — name candidate
27 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / INTRAMUSCULAR1486 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR24 mgExact identifier — unii candidate
134 equally ranked IID candidates
benzalkonium chlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SPRAY, METERED / NASAL1 mgName fallback — name candidate
24 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KINJECTION / INTRAVASCULAR0.48 mgExact identifier — unii candidate
77 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HINJECTION / INTRAMUSCULAR4 %w/vName fallback — name candidate
78 equally ranked IID candidates
hypromelloseHYPROMELLOSE3NXW29V3WOTABLET, FILM COATED / ORAL582 mgName fallback — name candidate
27 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HSOLUTION, GEL FORMING, EXTENDED RELEASE / OPHTHALMIC0.05 %w/wName fallback — name candidate
78 equally ranked IID candidates
hypromelloseHYPROMELLOSE3NXW29V3WOTABLET, EXTENDED RELEASE / ORAL1472 mgName fallback — name candidate
27 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HCAPSULE, COATED / ORAL0.04 mgName fallback — name candidate
78 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION / INTRAMUSCULAR9 mgExact identifier — unii candidate
134 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KINJECTION, SUSPENSION / INTRA-ARTICULAR1 mgExact identifier — unii candidate
77 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION/ DROPS / AURICULAR (OTIC)18 mgExact identifier — unii candidate
134 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KGEL / OPHTHALMIC396 mgExact identifier — unii candidate
77 equally ranked IID candidates
benzalkonium chlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION/ DROPS / AURICULAR (OTIC)0 %w/vName fallback — name candidate
24 equally ranked IID candidates
dibasic sodium phosphateSODIUM PHOSPHATE, DIBASICGR686LBA74INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS40 mgExact identifier — unii candidate
14 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, POWDER, FOR SOLUTION / INTRATHECAL1.35 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, SUSPENSION / INTRAVITREAL6 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSPRAY / NASAL30 mgExact identifier — unii candidate
134 equally ranked IID candidates
benzalkonium chlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION/ DROPS / OPHTHALMIC1 mgName fallback — name candidate
24 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KTABLET, COATED / ORAL0.21 mgExact identifier — unii candidate
77 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION, POWDER, FOR SOLUTION / INTRAPLEURAL226 mgExact identifier — unii candidate
134 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KDROPS / AURICULAR (OTIC)0.05 %w/wExact identifier — unii candidate
77 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HINJECTION, SOLUTION / INTRAVENOUS1170 mgName fallback — name candidate
78 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS19 mgExact identifier — unii candidate
77 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XLIQUID / INTRAVENOUS6320 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION/ DROPS / OPHTHALMIC55 mgExact identifier — unii candidate
134 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KINJECTION / SOFT TISSUE0.05 %w/vExact identifier — unii candidate
77 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / RETROBULBAR648 mgExact identifier — unii candidate
134 equally ranked IID candidates
hypromelloseHYPROMELLOSE3NXW29V3WOCREAM / TOPICAL0.1 %w/wName fallback — name candidate
27 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HSUSPENSION / SUBCUTANEOUS0.3 %w/vName fallback — name candidate
78 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HSUSPENSION / OPHTHALMIC1 mgName fallback — name candidate
78 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / INTRAVITREAL10 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KTABLET, DELAYED RELEASE / ORAL100 mgExact identifier — unii candidate
77 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KTABLET, ORALLY DISINTEGRATING / ORAL3 mgExact identifier — unii candidate
77 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HSUSPENSION / AURICULAR (OTIC)1 %w/vName fallback — name candidate
78 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSOLUTION / RECTALNAExact identifier — unii candidate
134 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KGEL / VAGINAL5 mgExact identifier — unii candidate
77 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HTABLET, EXTENDED RELEASE / ORAL10 mgName fallback — name candidate
78 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / SUBMUCOSAL17 mgExact identifier — unii candidate
134 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HSPRAY, METERED / NASAL0.1 mg/1mlName fallback — name candidate
78 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / INTRAVENOUS28773 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSUSPENSION / INTRATYMPANIC2 mgExact identifier — unii candidate
134 equally ranked IID candidates
benzalkonium chlorideBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / NASAL40.46 mg/100mlName fallback — name candidate
24 equally ranked IID candidates
polysorbate 80POLYSORBATE 806OZP39ZG8HSUSPENSION, EXTENDED RELEASE / ORAL40 mgName fallback — name candidate
78 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / INTRA-ARTERIAL278 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XINJECTION / INTRASYNOVIAL0.9 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XSYSTEM / IONTOPHORESIS6 mgExact identifier — unii candidate
134 equally ranked IID candidates
sodium chlorideSODIUM CHLORIDE451W47IQ8XLOTION / TOPICAL6 mgExact identifier — unii candidate
134 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N013422-001MAXIDEXDEXAMETHASONE0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982d4dbc9d85df4…
2026-10-15 13:18:302026-09N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982c2088c7a36db…
2026-09-14 22:38:342026-08N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 198284e616aacf4f…
2026-08-18 06:07:402026-07N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 19821e350fbaab3a…
2024-05-31 18:47 UTC2024-05N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 19828072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 19825c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 19825d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 19824b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 198274a2ff9319b5…
2022-03-09 01:35 UTC2022-03N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 198287673890dc5c…
2021-03-12 10:30 UTC2021-03N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 19825aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 19828869cabd3fbd…
2020-11-12 02:37 UTC2020-11N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982c0c555d07b60…
2019-12-14 00:12 UTC2019-12N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 19823f01610625f2…
2019-09-15 20:21 UTC2019-09N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982b00525d2431f…
2019-07-19 19:46 UTC2019-07N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 19826a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 19821c564ffb4f44…
2023-12-20 04:57 UTC2023-12N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 19829b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 19823f0d92c62455…
2023-05-13 08:27 UTC2023-05N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 1982053a50430f4f…
2023-01-26 05:58 UTC2023-01N013422-001MAXIDEX0.1%SUSPENSION/DROPS / OPHTHALMICRLD, RS, Approved before 19823bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
MAXIDEXDEXAMETHASONEHarrow Eye, LLC35e47fcd-e020-43e5-8322-41f8060d220d2025-05-05Warnings, Adverse reactionsName fallback
brand name: MAXIDEX

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.